PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow PTCT
PTC Therapeutics, Inc. (PTCT) EV/Sales
As of 16 October 2026, PTC Therapeutics, Inc. (PTCT) trades at a EV/Sales of 5.6×. Over the past ten years it has ranged from −1.7× (March 2016) to 89.0× (April 2015); the current reading is higher than 43% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | (33.77%) |
| FY2024 | 5.8× | 64.12% |
| FY2023 | 3.6× | (32.33%) |
| FY2022 | 5.3× | (12.01%) |
| FY2021 | 6.0× | (42.21%) |
| FY2020 | 10.3× | 29.35% |
| FY2019 | 8.0× | 38.90% |
| FY2018 | 5.8× | 75.36% |
| FY2017 | 3.3× | 8.98% |
| FY2016 | 3.0× | (86.85%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.4× | (3.66%) |
| Mar 2026 | 7.7× | 98.30% |
| Dec 2025 | 3.9× | 24.89% |
| Sep 2025 | 3.1× | 29.41% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. | 5.6× |
| TVTX Travere Therapeutics, Inc. compare | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | 8.7× |
| SRRK Scholar Rock Holding Corporation compare | 104× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| CGON CG Oncology, Inc. compare | 684× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)